How could Philips' launch of Oxygenate 5 affect Resmed's market position in India?
New oxygen concentrator launch increases competition for Resmed in India. The introduction of Oxygenate 5 by Philips into the Indian market increases competitive pressure on Resmed. Oxygenate 5 is a stationary oxygen concentrator designed for long-term supplemental oxygen therapy at home, targeting the significant burden of chronic respiratory conditions in India. The device offers features such as quieter operation at less than 40 dB, a digital flowmeter, and a 10,000-hour sieve warranty. As a major global health technology leader, Philips' entry into this growing segment of home respiratory care could intensify market competition for Resmed.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Resmed
-
Koninklijke Philips NV launched Oxygenate 5 in India on October 29, 2026. The stationary oxygen concentrator is designed for long-term supplemental oxygen use in the home environment. The device offers quieter operation at less than 40 dB, an easy-to-read digital flowmeter, and simplified routine maintenance.
The full event1independent outlet -
Koninklijke Philips NV and Resmed are known to be potential competitors facing re-entry into the U.S. medical device market, indicating they operate within the same respiratory device industry. The launch of a new, advanced oxygen concentrator by Philips in the Indian market, which has a high burden of chronic respiratory conditions, increases the competitive landscape for Resmed in the sector.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions
Everything about Resmed
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- COPD affects around 13% of adults in India, rising to 27% among those aged 60 and above.thehindubusinessline.com
- Oxygenate 5 delivers continuous oxygen flow from 0.5 to 5 L/min.thehindubusinessline.com
- The device offers quieter operation at less than 40 dB.thehindubusinessline.com
- Oxygenate 5 includes a 10,000-hour sieve warranty and a three-year limited warranty.thehindubusinessline.com
Why it matters
The Indian market presents a substantial opportunity for respiratory device manufacturers due to the significant burden of chronic respiratory conditions, with COPD affecting 13% of adults. For Resmed, this means that while the market need is high, the entry of a major global player like Philips with a feature-rich product could intensify the battle for market share and patient adoption.
Resmed operates in a competitive landscape, as evidenced by its known relationship with Philips as a potential competitor. The launch of Oxygenate 5, which is designed with patient-centric features and aims to simplify long-term care at home, directly targets the growing focus on home-based respiratory care, forcing competitors to reassess their market strategies and product offerings.
What we don't know yet
- What will the pricing strategy of Oxygenate 5 be relative to existing market offerings?
- How quickly will regulatory bodies in India approve and facilitate the distribution of the new device?
Is this still moving?
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- thehindubusinessline.comThursday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.